Diffusion Pharmaceuticals is a clinical stage biotechnology company focused on improving the results of cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, including multiple FDA Orphan-designated indications.
TSC modifies the tumor micro-environment, allowing enhanced therapeutic effects from radiation therapy and chemotherapy without the addition of harmful side effects.
Diffusion Pharmaceuticals is dedicated to extending the life expectancy of patients with treatment-resistant cancerous tumors, including GBM, pancreatic cancer and brain metastases.
A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (GBM). This open label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care, including a 37% improvement in overall survival over the control group at two years. A particularly strong efficacy signal was seen in the subset of inoperable patients where survival of TSC-treated patients at two years was increased by 380% over the controls.